CO2021001979A2 - Formas farmacéuticas orales biodisponibles - Google Patents

Formas farmacéuticas orales biodisponibles

Info

Publication number
CO2021001979A2
CO2021001979A2 CONC2021/0001979A CO2021001979A CO2021001979A2 CO 2021001979 A2 CO2021001979 A2 CO 2021001979A2 CO 2021001979 A CO2021001979 A CO 2021001979A CO 2021001979 A2 CO2021001979 A2 CO 2021001979A2
Authority
CO
Colombia
Prior art keywords
dosage forms
oral dosage
bioavailable oral
bioavailable
food
Prior art date
Application number
CONC2021/0001979A
Other languages
English (en)
Inventor
Mandar V Dali
Akm Nasir Uddin
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of CO2021001979A2 publication Critical patent/CO2021001979A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a composiciones farmacéuticas biodisponibles que tienen una mayor carga de dosis y una mejor disolución menos sujetas a un efecto de la comida.
CONC2021/0001979A 2018-08-03 2021-02-18 Formas farmacéuticas orales biodisponibles CO2021001979A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862714182P 2018-08-03 2018-08-03
PCT/US2019/044853 WO2020028778A1 (en) 2018-08-03 2019-08-02 Bioavailable oral dosage forms

Publications (1)

Publication Number Publication Date
CO2021001979A2 true CO2021001979A2 (es) 2021-03-08

Family

ID=67766269

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0001979A CO2021001979A2 (es) 2018-08-03 2021-02-18 Formas farmacéuticas orales biodisponibles

Country Status (23)

Country Link
US (1) US20210205225A1 (es)
EP (1) EP3829544A1 (es)
JP (1) JP2021532193A (es)
KR (1) KR20210041589A (es)
CN (1) CN112752570A (es)
AR (1) AR115913A1 (es)
AU (1) AU2019316036A1 (es)
BR (1) BR112021001859A2 (es)
CA (1) CA3107737A1 (es)
CL (1) CL2021000271A1 (es)
CO (1) CO2021001979A2 (es)
CR (1) CR20210093A (es)
EA (1) EA202190429A1 (es)
EC (1) ECSP21011795A (es)
IL (1) IL280471A (es)
MX (1) MX2021001364A (es)
NI (1) NI202100006A (es)
PE (1) PE20211410A1 (es)
PH (1) PH12021550237A1 (es)
SG (1) SG11202100984VA (es)
TN (1) TN2021000021A1 (es)
TW (1) TW202019414A (es)
WO (1) WO2020028778A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI671297B (zh) 2009-05-27 2019-09-11 Ｐｔｃ治療公司 治療癌症及非腫瘤病症之方法
EP3664803A4 (en) 2017-08-01 2021-05-05 PTC Therapeutics, Inc. DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS
CN112028888B (zh) * 2020-09-11 2021-08-20 中国药科大学 一种化合物及其制备方法和用途
US20220151938A1 (en) * 2022-01-28 2022-05-19 Ptc Therapeutics, Inc. Tablet for use in treating huntington's disease and method of making the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005219443A1 (en) 2004-03-03 2005-09-15 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
AU2005222632B2 (en) 2004-03-15 2012-02-09 Ptc Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
AU2008239598A1 (en) 2007-04-13 2008-10-23 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
SI2200588T1 (sl) 2007-09-25 2019-08-30 Solubest Ltd. Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo
US20090203709A1 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
US20120202801A1 (en) * 2009-05-27 2012-08-09 Liangxian Cao Methods for treating breast cancer
TWI671297B (zh) 2009-05-27 2019-09-11 Ｐｔｃ治療公司 治療癌症及非腫瘤病症之方法
EP3380079A4 (en) * 2015-11-25 2019-08-21 Patheon Development Services Inc. AMORPHOUS DISPERSION GRANULES AND PHARMACEUTICAL FORMS FOR ORAL USE

Also Published As

Publication number Publication date
WO2020028778A1 (en) 2020-02-06
PE20211410A1 (es) 2021-08-02
JP2021532193A (ja) 2021-11-25
PH12021550237A1 (en) 2021-10-11
KR20210041589A (ko) 2021-04-15
MX2021001364A (es) 2021-04-13
SG11202100984VA (en) 2021-02-25
EA202190429A1 (ru) 2021-06-15
AR115913A1 (es) 2021-03-10
CA3107737A1 (en) 2020-02-06
NI202100006A (es) 2021-05-21
IL280471A (en) 2021-03-25
TW202019414A (zh) 2020-06-01
CR20210093A (es) 2021-05-28
AU2019316036A1 (en) 2021-03-04
TN2021000021A1 (en) 2022-10-03
CN112752570A (zh) 2021-05-04
EP3829544A1 (en) 2021-06-09
US20210205225A1 (en) 2021-07-08
CL2021000271A1 (es) 2021-08-20
ECSP21011795A (es) 2021-03-31
BR112021001859A2 (pt) 2021-04-27

Similar Documents

Publication Publication Date Title
CO2021001979A2 (es) Formas farmacéuticas orales biodisponibles
SV2017005601A (es) Formulaciones farmacéuticas que contienen tenofovir y emtricitabina
CO2018004776A2 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
DK3727555T3 (da) Oral delivery of active drug substances
ES2715251R1 (es) Novedosa composicion farmaceutica que comprende particulas que comprenden un complejo de un polirribonucleotido de doble cadena y una polialquilenimina
EA201792591A1 (ru) Фармацевтические препараты
CY1122473T1 (el) Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης
MA55015A (fr) Formulations pharmaceutiques
CO2019015102A2 (es) Nuevos derivados de xantina sustituidos
CO2018014217A2 (es) Composiciones farmacéuticas que comprenden safinamida
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
EA201890477A1 (ru) Инкапсулированная композиция финголимода
EA201890929A1 (ru) Низкие дозировки композиций дипиридамола для перорального приема и их использование
PL3880171T3 (pl) Doustny preparat farmaceutyczny zawierający ibuprofen
EA202092800A1 (ru) Фармацевтическая композиция немедленного высвобождения для противовоспалительных лекарственных средств с фамотидином и карбонатом
CR20150411A (es) Composiciones farmacéuticas que contienen dexketoprofeno y tramadol
CO2019013645A2 (es) Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas
EA202091127A1 (ru) Фармацевтические композиции, включающие сафинамид
CR20170601A (es) Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina
CY1119636T1 (el) Φαρμακευτικο παρασκευασμα με βαση διοσμεκτιτη
CU20180036A7 (es) Composiciones terapéuticas para el tratamiento del virus de la inmunodeficiencia humana
EA201790387A1 (ru) Фармацевтическая композиция для лечения острой зубной боли или боли в челюсти
UA113237U (uk) Фармацевтична комбінація ацеклофенаку і снодійного або заспокійливого компонента
AR091835A1 (es) Una forma farmaceutica solida oral en dosis fija